Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Lynparza
Descriptions
Olaparib is used as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene. Your doctor will test for the presence of this gene. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.
Olaparib is used together with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of abnormal BRCA gene or a positive tumor test for genomic instability called HRD. Your doctor will test for the presence of this gene. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.
Olaparib is also used to treat ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene that has come back. Your doctor will test for the presence of this gene. It is used in patients who have received complete or partial treatment with platinum-based cancer medicines.
Olaparib is also used to treat HER2-negative early breast cancer in patients who have been treated with other cancer medicines. It is used if the cancer cells have the germline BRCA mutations. Your doctor will use a special test to look for these mutations. It is given to patients after surgery to remove the tumor.
Olaparib is also used to treat HER2-negative metastatic (cancer that has spread) breast cancer in patients who have been treated with other cancer medicines. It is used if the cancer cells have the germline BRCA mutations. Your doctor will use a special test to look for these mutations.
Olaparib is also used as maintenance treatment in patients with metastatic (cancer that has spread) pancreas cancer with a certain type of inherited (germline) abnormal BRCA gene, whose disease has not progressed and who have been treated with platinum-based cancer medicines for at least 16 weeks.
Olaparib is also used to treat metastatic castration-resistant prostate cancer (prostate cancer that has spread and is resistant to medical or surgical treatments that lower testosterone) in patients who have been treated with other cancer medicines (eg, abiraterone, enzalutamide). It is used if the cancer cells have a certain type of inherited (germline) or acquired (somatic) abnormal HRR gene. Your doctor will test for the presence of this gene.
Olaparib is used in combination with abiraterone and prednisone or prednisolone to treat metastatic castration-resistant prostate cancer (prostate cancer that has spread and is resistant to medical or surgical treatments that lower testosterone) with a certain type of inherited or acquired abnormal BRCA gene. Your doctor will test for the presence of this gene.
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: April 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.